Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
SOUTH SAN FRANCISCO, Calif., Aug. 09, 2017 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it will present at the 2017 Wedbush PacGrow Healthcare Conference in New York City on Wednesday, August 16 at 10:55 a.m. Eastern Time.
The presentation will be webcast live and available for replay from GBT’s website at www.globalbloodtx.com in the Investors section.
About Global Blood Therapeutics
Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. GBT is developing its lead product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease. GBT is also investigating GBT440 for the treatment of hypoxemic pulmonary disorders in two ongoing Phase 2a studies in patients with idiopathic pulmonary fibrosis. To learn more, please visit: www.globalbloodtx.com and follow the company on Twitter: @GBT_News.
Contact Information: Myesha Lacy (investors) GBT 650-351-4730 [email protected] Julie Normart (media) Pure Communications 415-946-1087 [email protected]
